The market has shown a positive trend, increasing by 1.7% over the last week and 20% over the past year, with earnings expected to grow significantly in the coming years. In such a climate, identifying stocks with strong financials becomes crucial for investors seeking opportunities beyond mainstream options. Penny stocks, despite their somewhat outdated moniker, remain relevant as investment choices due to their potential for growth and value when backed by solid fundamentals.

Let's uncover some gems from our specialized screener.

Compass Therapeutics (CMPX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology and other diseases in the United States, with a market cap of approximately $426.81 million.

Operations: Revenue Segments: No revenue segments have been reported.

Market Cap: $426.81M

Compass Therapeutics, Inc. is a pre-revenue biopharmaceutical firm with a market cap of US$426.81 million, focusing on antibody-based therapeutics. Despite its lack of revenue, the company maintains a strong financial position with short-term assets of US$180.9 million exceeding both short and long-term liabilities significantly. It has no debt and boasts a cash runway lasting over three years based on current free cash flow levels. However, recent challenges include being dropped from several Russell Growth Benchmarks and ongoing unprofitability with net losses increasing to US$25.15 million in Q2 2026 compared to the previous year’s figures.

Grab Holdings (GRAB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Grab Holdings Limited operates the Grab superapp across Southeast Asia, including countries like Cambodia, Indonesia, and Singapore, with a market cap of approximately $14.73 billion.

Operations: Grab Holdings Limited has not reported specific revenue segments.

Market Cap: $14.73B

Grab Holdings has demonstrated robust financial growth, with earnings rising 438.7% over the past year and net profit margins improving to 16%. The company reported Q2 2026 sales of US$997 million, up from US$819 million a year ago, alongside a significant increase in net income to US$252 million. Analysts expect continued growth with earnings projected to rise by 22.12% annually. Grab is executing a share repurchase program of up to $750 million funded by excess cash, indicating confidence in its financial health despite low return on equity at 7.3%. Short-term assets comfortably cover liabilities, enhancing stability.

Hyliion Holdings (HYLN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Hyliion Holdings Corp. designs and develops power generators for stationary and mobile applications, with a market cap of approximately $694.74 million.

Operations: The company generates revenue from its Auto Parts & Accessories segment, totaling $9.25 million.

Market Cap: $694.74M

Hyliion Holdings, despite being unprofitable and experiencing increased losses over the past five years, has shown potential with a significant $41.7 million military contract for its KARNO Power Modules. The company reported second-quarter revenue of US$4.94 million, up from US$1.52 million a year ago, and raised its 2026 revenue guidance by 50% to approximately US$15 million. Hyliion remains debt-free but is addressing cash flow concerns with recent capital raising efforts totaling $130.83 million through equity offerings and shelf registration filings, aiming to support ongoing development and operational needs amidst high share price volatility.

Make It Happen

• Jump into our full catalog of 327 US Penny Stocks here.
• Contemplating Other Strategies? The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.